| Identification | Back Directory | [Name]
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID | [CAS]
627865-18-3 | [Synonyms]
CAY10471
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID | [Molecular Formula]
C21H21FN2O4S | [MDL Number]
MFCD08062186 | [MOL File]
627865-18-3.mol | [Molecular Weight]
416.47 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:5): 0.5 mg/ml; Ethanol: 15 mg/ml | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CAY10471 (TM30089) is a potent, selective, and orally active prostaglandin D2 receptor CRTH2?antagonist. CAY10471 attenuates the progression of tubulointerstitial fibrosis and chronic contact hypersensitivity (CHS) in animal model[1][2][3]. | [in vivo]
CAY10471 (oral treatment; 2 mg/kg; challenged on day 22 or over 10 consecutive days) shows a diminished inflammation in chronic contact hypersensitivity (CHS) and IgE-CAI model. It blocks CRTH2 partly, but significantly suppresses inflammation in mice[2].CAY10471 (oral adminstration; 20 mg/kg; twice daily; beginning 3/4/5 days before UUO) significantly attenuates interstitial collagen deposition in the cortex when compared with the vehicle (8.40% versus 14.85%). Oral administration from 3 days after UUO also significantly attenuates interstitial collagen deposition in the cortex compared with vehicle (9.63% versus 14.44%). However, oral administration beginning 5 days after UUO has little effect on interstitial collagen deposition in the cortex when compared with vehicle (14.61% versus 15.09%). Unilateral ureteral obstruction (UUO)[3]. | Animal Model: | Balb/c mice, DP?/? mice, CRTH2?/? mice[2] | | Dosage: | 2 mg/kg | | Administration: | Oral treatment; once daily; challenged on day 22 or over 10 consecutive days | | Result: | Significantly suppressed both CHS and IgE-CAI inflammatory responses. |
| Animal Model: | C57BL/6 mice[3] | | Dosage: | 20 mg/kg | | Administration: | Oral treatment; twice daily; beginning 3/4/5 days before UUO | | Result: | Slowed the progression of renal fibrosis in the obstructed kidneys. |
| [IC 50]
CRTH2 | [References]
[1] Hatanaka M, et al. 15d-prostaglandin J2 enhancement of nerve growth factor-induced neurite outgrowth is blocked by the chemoattractant receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2)?antagonist?CAY10471 in PC12 cells. J Pharmacol Sci.?2010;113(1):89-93. Epub 2010 Apr 16. DOI:10.1254/jphs.10001sc
[2] Matsushima Y, et al. Distinct roles of prostaglandin D2 receptors in chronic skin inflammation.Mol Immunol. 2011 Oct;49(1-2):304-10. DOI:10.1016/j.molimm.2011.08.023
[3] Ito H, et al. PGD2-CRTH2?pathway promotes tubulointerstitial fibrosis.J Am Soc Nephrol.?2012 Nov;23(11):1797-809. DOI:10.1681/ASN.2012020126 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
amyjet
|
| Tel: |
4006800868;027-59626688 18371453821;18771149750 |
| Website: |
http://www.amyjet.com/ |
| Company Name: |
Abcam Limited
|
| Tel: |
021-2070050 400921018 |
| Website: |
www.abcam.cn |
|